Why did 1AD.AX stock fall pre-market today?

1AD.AX stock fell on 20 Mar 2026 due to funding and trial timing concerns. Low relative volume of **0.22** amplified price moves. Investors priced in cash runway risk ahead of the company earnings date on 2026-08-21.

What are the key financials for 1AD.AX stock to watch?

Watch EPS **-0.01**, current ratio **0.89**, market cap **A$391,678.00**, and cash per share **A$0.00101**. These metrics show tight liquidity and the potential need for capital raises.

What is Meyka AI’s forecast for 1AD.AX stock?

Meyka AI's forecast projects **A$0.00700** in 12 months for 1AD.AX stock, implying **+133.33%** upside from A$0.003. Forecasts are model-based projections and not guarantees.

How does sector performance affect 1AD.AX stock?

The biotech segment is volatile with a 3-month sector drop of **-10.86%**. Sector weakness increases sensitivity to clinical and financing news for small caps like 1AD.AX.

AU Stocks

AdAlta (1AD.AX) down 25% pre-market at A$0.003 on 20 Mar 2026: cash burn risk

ByHuzaifa Zahoor March 20, 2026March 20, 2026

The 1AD.AX stock fell 25.00% pre-market to A$0.003, a sharp move on low market depth ahead of the ASX open on 20 Mar 2026. Volume at 1,894,578 shares is below the 50-day average of 8,474,973, but the drop highlights investor concern about cash runway and trial timelines. AdAlta Limited (1AD.AX) is a clinical-stage biotech on the ASX with a market cap of A$391,678.00 and negative EPS of -0.01. We run through drivers, ratios, technicals and a Meyka AI model forecast to frame the outlook for traders and holders.